H₂FPEF Score
Estimation of probability of heart failure with preserved ejection fraction
További információk
Figyelmeztetés
Ez az eszköz kizárólag oktatási célra szolgál, és nem jelent vagy helyettesít szakmai tanácsot. Az eszköz nem használható orvosi diagnózis felállítására és/vagy orvosi kezelés nyújtására.
General description
Heart failure represents one of the leading causes of morbidity and mortality globally. Despite its frequency, the diagnosis of heart failure with preserved ejection fraction (HFpEF) is challenging. The H₂FPEF score was designed to estimate the probability of underlying HFpEF in the patients presenting with unexplained exertional dyspnea.
The H₂FPEF score consists of 6 clinical and echocardiographic characteristics that can be universally obtained in the evaluation of patients with unexplained exertional dyspnea (body mass index, age, antihypertensive medication, presence of atrial fibrillation, echocardiographic E/e’ ratio, and echocardiographic estimate of pulmonary artery systolic pressure).
Two implementations were developed. A simple points-based score that ranges from 0 to 9 can be used to stratify patients into low (< 2), intermediate (2–5) or high (≥ 6) probability categories for HFpEF. Additionally, the more complex continuous score model can be used for a more precise estimation of HFpEF probability; this model excludes the antihypertensive medication category.
The H₂FPEF score has been externally validated and is recommended by the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure to facilitate discrimination of HFpEF from noncardiac causes of dyspnea and to assist in determination of the need for further diagnostic testing in the evaluation of patients with unexplained exertional dyspnea.
Heart failure represents one of the leading causes of morbidity and mortality globally. Despite its frequency, the diagnosis of heart failure with preserved ejection fraction (HFpEF) is challenging. The H₂FPEF score was designed to estimate the probability of underlying HFpEF in the patients presenting with unexplained exertional dyspnea.
The H₂FPEF score consists of 6 clinical and echocardiographic characteristics that can be universally obtained in the evaluation of patients with unexplained exertional dyspnea (body mass index, age, antihypertensive medication, presence of atrial fibrillation, echocardiographic E/e’ ratio, and echocardiographic estimate of pulmonary artery systolic pressure).
Two implementations were developed. A simple points-based score that ranges from 0 to 9 can be used to stratify patients into low (< 2), intermediate (2–5) or high (≥ 6) probability categories for HFpEF. Additionally, the more complex continuous score model can be used for a more precise estimation of HFpEF probability; this model excludes the antihypertensive medication category.
The H₂FPEF score has been externally validated and is recommended by the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure to facilitate discrimination of HFpEF from noncardiac causes of dyspnea and to assist in determination of the need for further diagnostic testing in the evaluation of patients with unexplained exertional dyspnea.
Result ranges for points-based model
Low probability of HFpEF
< 2Intermediate probability
2–5High probability of HFpEF
≥ 6Formula for points-based model
Two or more hypertensive medicines, Pulmonary Artery Systolic Pressure > 35 mmHg, age > 60 years and E/e' ratio > 9 are assigned 1 point.
BMI > 30 kg/m2 is assigned 2 points.
Presence of atrial fibrillation (paroxysmal or persistent) is assigned 3 points.
BMI > 30 kg/m2 is assigned 2 points.
Presence of atrial fibrillation (paroxysmal or persistent) is assigned 3 points.
Formula for continuous model
Probability of HFpEF = X/(1+ X)*100
X = ey
y = -9.19174463966566 + 0.0451129471272832*Age [years] + 0.130730156015681*BMI [kg/m2] + 0.0858634402456586*E/e' ratio + 0.051963758732548*Pulmonary artery systolic pressure [mmHg] + 1.69968057294513*Atrial fibrillation (1 if yes, 0 if no)
X = ey
y = -9.19174463966566 + 0.0451129471272832*Age [years] + 0.130730156015681*BMI [kg/m2] + 0.0858634402456586*E/e' ratio + 0.051963758732548*Pulmonary artery systolic pressure [mmHg] + 1.69968057294513*Atrial fibrillation (1 if yes, 0 if no)
References
Verzió
1
Az eszközről
Heart failure represents one of the leading causes of morbidity and mortality globally. Despite its frequency, the diagnosis of heart failure with preserved ejection fraction (HFpEF) is challenging. The H₂FPEF score was designed to estimate the probability of underlying HFpEF in the patients presenting with unexplained exertional dyspnea.
The H₂FPEF score consists of 6 clinical and echocardiographic characteristics that can be universally obtained in the evaluation of patients with unexplained exertional dyspnea (body mass index, age, antihypertensive medication, presence of atrial fibrillation, echocardiographic E/e’ ratio, and echocardiographic estimate of pulmonary artery systolic pressure).
Two implementations were developed. A simple points-based score that ranges from 0 to 9 can be used to stratify patients into low (< 2), intermediate (2–5) or high (≥ 6) probability categories for HFpEF. Additionally, the more complex continuous score model can be used for a more precise estimation of HFpEF probability; this model excludes the antihypertensive medication category.
The H₂FPEF score has been externally validated and is recommended by the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure to facilitate discrimination of HFpEF from noncardiac causes of dyspnea and to assist in determination of the need for further diagnostic testing in the evaluation of patients with unexplained exertional dyspnea.
The H₂FPEF score consists of 6 clinical and echocardiographic characteristics that can be universally obtained in the evaluation of patients with unexplained exertional dyspnea (body mass index, age, antihypertensive medication, presence of atrial fibrillation, echocardiographic E/e’ ratio, and echocardiographic estimate of pulmonary artery systolic pressure).
Two implementations were developed. A simple points-based score that ranges from 0 to 9 can be used to stratify patients into low (< 2), intermediate (2–5) or high (≥ 6) probability categories for HFpEF. Additionally, the more complex continuous score model can be used for a more precise estimation of HFpEF probability; this model excludes the antihypertensive medication category.
The H₂FPEF score has been externally validated and is recommended by the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure to facilitate discrimination of HFpEF from noncardiac causes of dyspnea and to assist in determination of the need for further diagnostic testing in the evaluation of patients with unexplained exertional dyspnea.
